B
Brian K. Hubbard
Researcher at Merck & Co.
Publications - 75
Citations - 3940
Brian K. Hubbard is an academic researcher from Merck & Co.. The author has contributed to research in topics: Cholesterol & LDL receptor. The author has an hindex of 29, co-authored 74 publications receiving 3585 citations. Previous affiliations of Brian K. Hubbard include University of Washington & Novartis.
Papers
More filters
Journal ArticleDOI
Dissociation of Hepatic Steatosis and Insulin Resistance in Mice Overexpressing DGAT in the Liver
Mara Monetti,Malin Levin,Matthew J. Watt,Mini P. Sajan,Stephen Marmor,Brian K. Hubbard,Robert Stevens,James R. Bain,Christopher B. Newgard,Robert V. Farese,Andrea L. Hevener +10 more
TL;DR: The results indicate that DGAT-mediated lipid accumulation in the liver is insufficient to cause insulin resistance and show that hepatic steatosis can occur independently of insulin resistance.
Journal ArticleDOI
Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib
Laurent Yvan-Charvet,Jelena Kling,Tamara A. Pagler,Hongna Li,Brian K. Hubbard,Timothy S. Fisher,Carl P. Sparrow,Andrew K. P. Taggart,Alan R. Tall +8 more
TL;DR: Niacin treatment caused a moderate increase in the ability of HDL to promote net cholesterol efflux, whereas inhibition of cholesteryl ester transfer protein via anacetrapib led to a more dramatic increase in association with enhanced particle functionality at higher HDL concentrations.
Journal ArticleDOI
Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH
Paola Lo Surdo,Matthew J. Bottomley,Alessandra Calzetta,Ethan C. Settembre,Agostino Cirillo,Shilpa Pandit,Yan G. Ni,Brian K. Hubbard,Ayesha Sitlani,Andrea Carfi +9 more
TL;DR: PCSK9 seems to hold LDLR in an extended conformation and to interfere with conformational rearrangements required for LDLR recycling, as well as cofactor binding and interaction with LDLR epidermal growth factor and β‐propeller domains.
Journal ArticleDOI
DGAT1-dependent triacylglycerol storage by macrophages protects mice from diet-induced insulin resistance and inflammation
Suneil K. Koliwad,Ryan S. Streeper,Mara Monetti,Ivo Cornelissen,Liana Chan,Koji Terayama,Stephen Naylor,Meghana Rao,Brian K. Hubbard,Robert V. Farese +9 more
TL;DR: Increasing DGAT1 expression in murine macrophages increases their capacity for TG storage, protects against FA-induced inflammatory activation, and is sufficient to reduce the inflammatory and metabolic consequences of DIO.
Journal ArticleDOI
A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo
Yan G. Ni,Stefania Di Marco,Jon H. Condra,Laurence B. Peterson,Weirong Wang,Fubao Wang,Shilpa Pandit,Holly A. Hammond,Ray Rosa,Richard T. Cummings,Dana D. Wood,Xiaomei Liu,Matthew J. Bottomley,Xun Shen,Rose M. Cubbon,Sheng-Ping Wang,Douglas G. Johns,Cinzia Volpari,Lora Hamuro,Jayne Chin,Lingyi Huang,Jing Zhang Zhao,Salvatore Vitelli,Peter Haytko,Douglas Wisniewski,Lyndon J. Mitnaul,Carl P. Sparrow,Brian K. Hubbard,Andrea Carfi,Ayesha Sitlani +29 more
TL;DR: The results clearly demonstrate that the LDL-lowering effect of the neutralizing anti-PCSK9 1D05-IgG2 antibody is mediated by reducing the amount of PCSK9 that can bind to the LDLr.